» Articles » PMID: 39256811

Lipid Metabolism Reprogramming in Endometrial Cancer: Biological Functions and Therapeutic Implications

Overview
Publisher Biomed Central
Date 2024 Sep 10
PMID 39256811
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Endometrial cancer is one of the major gynecological cancers, with increasing incidence and mortality in the past decades. Emerging preclinical and clinical data have indicated its close association with obesity and dyslipidemia. Metabolism reprogramming has been considered as the hallmark of cancer, to satisfy the extensive need of nutrients and energy for survival and growth. Particularly, lipid metabolism reprogramming has aroused the researchers' interest in the field of cancer, including tumorigenesis, invasiveness, metastasis, therapeutic resistance and immunity modulation, etc. But the roles of lipid metabolism reprogramming in endometrial cancer have not been fully understood. This review has summarized how lipid metabolism reprogramming induces oncogenesis and progression of endometrial cancer, including the biological functions of aberrant lipid metabolism pathway and altered transcription regulation of lipid metabolism pathway. Besides, we proposed novel therapeutic strategies of targeting lipid metabolism pathway and concentrated on its potential of sensitizing immunotherapy and hormonal therapy, to further optimize the existing treatment modalities of patients with advanced/metastatic endometrial cancer. Moreover, we expect that targeting lipid metabolism plus hormone therapy may block the endometrial malignant transformation and enrich the preventative approaches of endometrial cancer.

Conclusion: Lipid metabolism reprogramming plays an important role in tumor initiation and cancer progression of endometrial cancer. Targeting the core enzymes and transcriptional factors of lipid metabolism pathway alone or in combination with immunotherapy/hormone treatment is expected to decrease the tumor burden and provide promising treatment opportunity for patients with advanced/metastatic endometrial cancer.

Citing Articles

Advancements in Minimally Invasive Techniques and Biomarkers for the Early Detection of Endometrial Cancer: A Comprehensive Review of Novel Diagnostic Approaches and Clinical Implications.

Asaturova A, Zaretsky A, Rogozhina A, Tregubova A, Badlaeva A J Clin Med. 2025; 13(24.

PMID: 39768459 PMC: 11728107. DOI: 10.3390/jcm13247538.


Genetically Proxied Therapeutic Effect of Lipid-Lowering Drugs Use, Breast Cancer, and Endometrial Cancer's Risk: A Drug Target-Based Mendelian Randomization Study.

Dang C, Wang X, Liu P, Liu J, Yu X Int J Womens Health. 2024; 16:2033-2041.

PMID: 39633845 PMC: 11614999. DOI: 10.2147/IJWH.S468733.

References
1.
Schointuch M, Gilliam T, Stine J, Han X, Zhou C, Gehrig P . Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer. Gynecol Oncol. 2014; 134(2):346-55. PMC: 4125536. DOI: 10.1016/j.ygyno.2014.05.015. View

2.
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

3.
Luo J, Yang H, Song B . Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2019; 21(4):225-245. DOI: 10.1038/s41580-019-0190-7. View

4.
Fhu C, Ali A . Fatty Acid Synthase: An Emerging Target in Cancer. Molecules. 2020; 25(17). PMC: 7504791. DOI: 10.3390/molecules25173935. View

5.
McKillop I, Girardi C, Thompson K . Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal. 2019; 62:109336. DOI: 10.1016/j.cellsig.2019.06.001. View